Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Kuros Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KURN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: KURN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
1 Year Return
Return vs Industry: KURN underperformed the Swiss Biotechs industry which returned 25.1% over the past year.
Return vs Market: KURN underperformed the Swiss Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kuros Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StReflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
4 months ago | Simply Wall StWhat We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
6 months ago | Simply Wall StKuros Biosciences' (VTX:KURN) Stock Price Has Reduced 82% In The Past Three Years
Is Kuros Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KURN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KURN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KURN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: KURN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KURN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KURN is good value based on its PB Ratio (0.8x) compared to the CH Biotechs industry average (6.2x).
How is Kuros Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kuros Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Kuros Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KURN is currently unprofitable.
Growing Profit Margin: KURN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KURN is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare KURN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KURN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5%).
Return on Equity
High ROE: KURN has a negative Return on Equity (-13.62%), as it is currently unprofitable.
How is Kuros Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: KURN's short term assets (CHF34.0M) exceed its short term liabilities (CHF3.9M).
Long Term Liabilities: KURN's short term assets (CHF34.0M) exceed its long term liabilities (CHF5.9M).
Debt to Equity History and Analysis
Debt Level: KURN is debt free.
Reducing Debt: KURN has no debt compared to 5 years ago when its debt to equity ratio was 32.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KURN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KURN has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 11% each year.
What is Kuros Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KURN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KURN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KURN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KURN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KURN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joost de Bruijn (54 yo)
Prof. Joost D. de Bruijn, B.Sc. Ph.D., has been Chief Executive Officer of Kuros Biosciences AG since December 4, 2017 and its Director since June 14, 2018. Prof. Dr. de Bruijn was the Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Joost's total compensation ($USD551.85K) is about average for companies of similar size in the Swiss market ($USD479.49K).
Compensation vs Earnings: Joost's compensation has increased whilst the company is unprofitable.
Experienced Management: KURN's management team is considered experienced (3.2 years average tenure).
Experienced Board: KURN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.1%.
Kuros Biosciences AG's company bio, employee growth, exchange listings and data sources
- Name: Kuros Biosciences AG
- Ticker: KURN
- Exchange: SWX
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF68.212m
- Shares outstanding: 32.79m
- Website: https://www.kuros.ch
Number of Employees
- Kuros Biosciences AG
- Wagistrasse 25
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the Uni...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/09 17:06|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.